Article Details

Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA ...

Retrieved on: 2022-12-10 23:41:01

Tags for this article:

Click the tags to see associated articles and topics

Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA .... View article details on hiswai:

Excerpt

Tifcemalimab is the world's first-in-human anti-tumor anti-BTLA monoclonal antibody independently developed by the company.

Article found on: www.globenewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up